{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:24:45Z","timestamp":1780410285430,"version":"3.54.1"},"reference-count":78,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Background: Type 2 diabetes (T2D) is a low-grade inflammatory condition with abnormalities in the immune response mediated by T lymphocytes and macrophages. Drug repositioning for immunomodulatory molecules is an attractive proposal for treating T2D. Nitazoxanide (NTZ) is a broad-spectrum drug with promising immunomodulatory effects. Thus, we investigated the immunomodulatory effect of NTZ on peripheral blood mononuclear cells (PBMCs) from patients with T2D. Methods: Fifty patients with T2D were selected, and the proliferative response of T lymphocytes and the M1\/M2 ratio of macrophages post cell culture were evaluated by flow cytometry, as well as measuring the concentration of cytokines by ELISA and the relative expression of microRNAs (miRNAs) related to the immune response by real-time PCR. Results: NTZ exerts an inhibitory effect on the cell proliferation of T lymphocytes stimulated with anti-CD3 and anti-CD28 antibodies without modifying cell viability, and significant decreases in the supernatant concentrations of interleukin (IL)-1\u03b2, IL-2, IL-6, IL-10, and IL-12. Furthermore, NTZ negatively regulates the relative expression of miR-155-5p without changes in miR-146a-5p. The M1\/M2 ratio of monocytes\/macrophages decreased the M1 and increased the M2 subpopulation by NTZ. Conclusions: Our results suggest that NTZ exerts immunomodulatory effects on PBMCs from T2D patients, and shows potential alternative therapeutic benefits.<\/jats:p>","DOI":"10.3390\/biom11121817","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T21:19:08Z","timestamp":1638479948000},"page":"1817","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nitazoxanide Exerts Immunomodulatory Effects on Peripheral Blood Mononuclear Cells from Type 2 Diabetes Patients"],"prefix":"10.3390","volume":"11","author":[{"given":"Mauricio","family":"Castillo-Salazar","sequence":"first","affiliation":[{"name":"Pharmacy Faculty, Universidad Aut\u00f3noma del Estado de Morelos, Cuernavaca 62209, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6556-1632","authenticated-orcid":false,"given":"Fausto","family":"S\u00e1nchez-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Immunology Department, Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez, Tlalpan, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashidi","family":"Springall del Villar","sequence":"additional","affiliation":[{"name":"Immunology Department, Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez, Tlalpan, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-4762","authenticated-orcid":false,"given":"Gabriel","family":"Navarrete-V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Pharmacy Faculty, Universidad Aut\u00f3noma del Estado de Morelos, Cuernavaca 62209, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6569-2851","authenticated-orcid":false,"given":"Adri\u00e1n","family":"Hern\u00e1ndez-DiazCouder","sequence":"additional","affiliation":[{"name":"Immunology Department, Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez, Tlalpan, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mojica-Cardoso","sequence":"additional","affiliation":[{"name":"Pathology Laboratory, Hospital del Ni\u00f1o Morelense, Cuernavaca 62275, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Garc\u00eda-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Pharmacy Faculty, Universidad Aut\u00f3noma del Estado de Morelos, Cuernavaca 62209, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cairo","family":"Toledano-Jaimes","sequence":"additional","affiliation":[{"name":"Pharmacy Faculty, Universidad Aut\u00f3noma del Estado de Morelos, Cuernavaca 62209, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"Bernal-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Pharmacy Faculty, Universidad Aut\u00f3noma del Estado de Morelos, Cuernavaca 62209, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.humimm.2014.02.007","article-title":"The alteration of Th1\/Th2\/Th17\/Treg paradigm in patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy","volume":"75","author":"Zhang","year":"2014","journal-title":"Hum. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A.A., and Ogurtsova, K. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract., 157.","DOI":"10.1016\/j.diabres.2019.107843"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11892-004-0074-9","article-title":"Endothelial dysfunction, inflammation, and insulin resistance: A focus on subjects at risk for type 2 diabetes","volume":"4","author":"Caballero","year":"2004","journal-title":"Curr. Diabetes Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2337\/diacare.27.3.813","article-title":"Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabletes","volume":"27","author":"Pickup","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/ATVBAHA.108.165100","article-title":"T-lymphocyte infiltration in visceral adipose tissue: A primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance","volume":"28","author":"Kintscher","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_6","first-page":"442","article-title":"Type 2 Diabetes and its Impact on the Immune System","volume":"16","author":"Berbudi","year":"2019","journal-title":"Curr. Diabetes Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6494795","DOI":"10.1155\/2017\/6494795","article-title":"Role of T Lymphocytes in Type 2 Diabetes and Diabetes-Associated Inflammation","volume":"2017","author":"Xia","year":"2017","journal-title":"J. Diabetes Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Francisco, C.O., Catai, A.M., Moura-Tonello, S.C.G., Arruda, L.C.M., Lopes, S.L.B., Benze, B.G., Del Vale, A.M., Malmegrim, K.C.R., and Leal, A.M.O. (2016). Cytokine profile and lymphocyte subsets in type 2 diabetes. Braz. J. Med. Biol. Res., 49.","DOI":"10.1590\/1414-431X20155062"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13643-018-0835-1","article-title":"T cell activation and cardiovascular risk in type 2 diabetes mellitus: A protocol for a systematic review and meta-analysis","volume":"7","author":"Nyambuya","year":"2018","journal-title":"Syst. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.it.2003.10.013","article-title":"Inflammation: The link between insulin resistance, obesity and diabetes","volume":"25","author":"Dandona","year":"2004","journal-title":"Trends Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ni.f.209","article-title":"MicroRNAs: New regulators of immune cell development and function","volume":"9","author":"Baltimore","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1172\/JCI29881","article-title":"Obesity induces a phenotypic switch in adipose tissue macrophage polarization","volume":"117","author":"Lumeng","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/139239","article-title":"Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines","volume":"2013","author":"Makki","year":"2013","journal-title":"ISRN Inflamm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nri3071","article-title":"Macrophage-mediated inflammation in metabolic disease","volume":"11","author":"Chawla","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1016\/j.febslet.2005.05.031","article-title":"Adipose tissues as an ancestral immune organ: Site-specific change in obesity","volume":"579","author":"Cousin","year":"2005","journal-title":"FEBS Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.devcel.2006.09.009","article-title":"The diverse functions of microRNAs in animal development and disease","volume":"11","author":"Kloosterman","year":"2006","journal-title":"Dev. Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.3748\/wjg.v19.i20.2985","article-title":"Role of microRNAs in the immune system, inflammation and cancer","volume":"19","author":"Raisch","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nri.2016.40","article-title":"MicroRNAs as regulatory elements in immune system logic","volume":"16","author":"Mehta","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41467-017-00972-z","article-title":"An NF-\u03baB-microRNA regulatory network tunes macrophage inflammatory responses","volume":"8","author":"Mann","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., Castelli, G., and Labbaye, C. (2017). miR-146 and miR-155: Two key modulators of immune response and tumor development. Non-Coding RNA, 3.","DOI":"10.3390\/ncrna3030022"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1517\/14656566.7.7.953","article-title":"Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections","volume":"7","author":"Hemphill","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0377-1237(11)80020-1","article-title":"Nitazoxanide: A broad spectrum antimicrobial","volume":"67","author":"Singh","year":"2011","journal-title":"Med. J. Armed Forces India"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: A first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antiviral Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s12272-019-01202-4","article-title":"Tizoxanide induces autophagy by inhibiting PI3K\/Akt\/mTOR pathway in RAW264.7 macrophage cells","volume":"43","author":"Shou","year":"2020","journal-title":"Arch. Pharm. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.intimp.2012.03.002","article-title":"Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice","volume":"13","author":"Hong","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1139\/cjpp-2017-0533","article-title":"Time-dependent therapeutic roles of nitazoxanide on high-fat diet\/streptozotocin-induced diabetes in rats: Effects on hepatic peroxisome proliferator-activated receptor-gamma receptors","volume":"96","author":"Elaidy","year":"2018","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s43141-020-00055-5","article-title":"Drug repurposing of nitazoxanide: Can it be an effective therapy for COVID-19?","volume":"18","author":"Mahmoud","year":"2020","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1166\/jnn.2014.8647","article-title":"Encapsulation of the antimicrobial and immunomodulator agent nitazoxanide within polymeric micelles","volume":"14","author":"Glisoni","year":"2014","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_32","unstructured":"(2020, December 08). Nitazoxanide|C12H9N3O5S, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Nitazoxanide."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.talanta.2012.02.014","article-title":"Identification, characterization and cytotoxicity in vitro assay of nitazoxanide major degradation product","volume":"93","author":"Malesuik","year":"2012","journal-title":"Talanta"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3923\/jbs.2016.120.127","article-title":"Nanocapsulation of nitazoxanide in solid lipid nanoparticles as a new drug delivery system and in vitro release study","volume":"16","author":"Abbasalipourkabir","year":"2016","journal-title":"J. Biol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/0974-7788.59946","article-title":"Sample size calculation","volume":"1","author":"Bhalerao","year":"2010","journal-title":"Int. J. Ayurveda Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5114\/ceji.2020.94670","article-title":"Th17 and regulatory T cells in patients with different time of progression of type 2 diabetes mellitus","volume":"45","year":"2020","journal-title":"Cent. J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.imbio.2015.02.007","article-title":"Expression of CD73 and A2A receptors in cells from subjects with obesity and type 2 diabetes mellitus","volume":"220","year":"2015","journal-title":"Immunobiology"},{"key":"ref_38","unstructured":"(2021, November 22). eBioscienceTM Cell Proliferation Dye eFluorTM 670. Available online: https:\/\/www.thermofisher.com\/order\/catalog\/product\/65-0840-85."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0022-1759(03)00010-3","article-title":"T cell stimulation and expansion using anti-CD3\/CD28 beads","volume":"275","author":"Trickett","year":"2003","journal-title":"J. Immunol. Methods"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-1759(90)90210-M","article-title":"The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells","volume":"128","author":"Riddell","year":"1990","journal-title":"J. Immunol. Methods"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.3389\/fimmu.2018.02148","article-title":"Control of immunoregulatory molecules by miRNAs in T cell activation","volume":"9","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.4049\/jimmunol.1002615","article-title":"Elevated Proinflammatory Cytokine Production by a Skewed T Cell Compartment Requires Monocytes and Promotes Inflammation in Type 2 Diabetes","volume":"186","author":"McDonnell","year":"2011","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00011-019-01265-5","article-title":"The increased T helper cells proliferation and inflammatory responses in patients with type 2 diabetes mellitus is suppressed by sitagliptin and vitamin D3 in vitro","volume":"68","author":"Sheikh","year":"2019","journal-title":"Inflamm. Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Redondo-Sendino, A., Guallar-Castill\u00f3n, P., Banegas, J.R., and Rodr\u00edguez-Artalejo, F. (2006). Gender differences in the utilization of health care. BMC Public Health, 6.","DOI":"10.1186\/1471-2458-6-155"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2337\/diacare.28.3.514","article-title":"Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes","volume":"28","author":"Wexler","year":"2005","journal-title":"Diabetes Care"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1590\/S1806-83242009000300006","article-title":"A simple method to measure cell viability in proliferation and cytotoxicity assays","volume":"23","author":"Borra","year":"2009","journal-title":"Braz. Oral Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2174\/1389201017666160808160513","article-title":"Cell Proliferation and Cytotoxicity Assays","volume":"17","author":"Adan","year":"2016","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/jac\/45.4.453","article-title":"Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture","volume":"45","author":"Giacometti","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_49","first-page":"265","article-title":"Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection","volume":"48","author":"Hu","year":"2013","journal-title":"Ann. Rep. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1084\/jem.167.3.1253","article-title":"B cell stimulating factor 2\/interleukin 6 is a costimulant for human thymocytes and T lymphocytes","volume":"167","author":"Lotz","year":"1988","journal-title":"J. Exp. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"29820","DOI":"10.18632\/oncotarget.25661","article-title":"Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer","volume":"9","author":"Vainer","year":"2018","journal-title":"Oncotarget"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2018.04.004","article-title":"IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets","volume":"41","author":"Unver","year":"2018","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.185.3.461","article-title":"Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells","volume":"185","author":"Anguita","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.4049\/jimmunol.169.7.3637","article-title":"IL-12 Provides Proliferation and Survival Signals to Murine CD4 + T Cells Through Phosphatidylinositol 3-Kinase\/Akt Signaling Pathway","volume":"169","author":"Yoo","year":"2002","journal-title":"J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1128\/IAI.67.11.5747-5754.1999","article-title":"Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine","volume":"67","author":"Leal","year":"1999","journal-title":"Infect. Immun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/intimm\/dxl007","article-title":"IL-1\u03b2, but not IL-1\u03b1, is required for antigen-specific T cell activation and the induction of local inflammation in the delayed-type hypersensitivity responses","volume":"18","author":"Nambu","year":"2006","journal-title":"Int. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1046\/j.1365-2567.2002.01501.x","article-title":"Interleukin-6 promotes the production of interleukin-4 and interleukin-5 by interleukin-2-dependent and -independent mechanisms in freshly isolated human T cells","volume":"107","author":"Heijink","year":"2002","journal-title":"Immunology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0148607104028006410","article-title":"Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity","volume":"28","author":"Khaodhiar","year":"2004","journal-title":"J. Parenter. Enter. Nutr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2040622312466908","article-title":"Tocilizumab in rheumatoid arthritis: Efficacy, safety and its place in therapy","volume":"4","author":"Kaneko","year":"2013","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"a034470","DOI":"10.1101\/cshperspect.a034470","article-title":"Daclizumab therapy for multiple sclerosis","volume":"9","author":"Bielekova","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"12481","DOI":"10.1073\/pnas.0605298103","article-title":"NF-\u03baB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses","volume":"103","author":"Taganov","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Balde\u00f3n R, L., Weigelt, K., de Wit, H., Ozcan, B., van Oudenaren, A., Semp\u00e9rtegui, F., Sijbrands, E., Grosse, L., Freire, W., and Drexhage, H.A. (2014). Decreased Serum Level of miR-146a as Sign of Chronic Inflammation in Type 2 Diabetic Patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115209"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mad.2019.03.001","article-title":"Circulating miR-146a in healthy aging and type 2 diabetes: Age- and gender-specific trajectories","volume":"180","author":"Giuliani","year":"2019","journal-title":"Mech. Ageing Dev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.cell.2010.08.012","article-title":"Function of miR-146a in Controlling Treg Cell-Mediated Regulation of Th1 Responses","volume":"142","author":"Lu","year":"2010","journal-title":"Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.4049\/jimmunol.0900707","article-title":"MicroRNA-146a Feedback Inhibits RIG-I-Dependent Type I IFN Production in Macrophages by Targeting TRAF6, IRAK1, and IRAK2","volume":"183","author":"Hou","year":"2009","journal-title":"J. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1073\/pnas.0610731104","article-title":"MicroRNA-155 is induced during the macrophage inflammatory response","volume":"104","author":"Taganov","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.00799","article-title":"MicroRNAs as molecular switches in macrophage activation","volume":"10","author":"Curtale","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/SHK.0000000000000604","article-title":"MiRNA-mediated macrophage polarization and its potential role in the regulation of inflammatory response","volume":"46","author":"Essandoh","year":"2016","journal-title":"Shock"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jlb.67.1.97","article-title":"Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli","volume":"67","author":"Buechler","year":"2000","journal-title":"J. Leukoc. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.clim.2008.09.011","article-title":"Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients","volume":"130","author":"Moniuszko","year":"2009","journal-title":"Clin. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"523652","DOI":"10.1155\/2013\/523652","article-title":"The haptoglobin-cd163-heme oxygenase-1 pathway for hemoglobin scavenging","volume":"2013","author":"Thomsen","year":"2013","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6549242","DOI":"10.1155\/2017\/6549242","article-title":"The Association between Monocyte Surface CD163 and Insulin Resistance in Patients with Type 2 Diabetes","volume":"2017","author":"Kawarabayashi","year":"2017","journal-title":"J. Diabetes Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1479164111430242","article-title":"Impaired alternative macrophage differentiation of peripheral blood mononuclear cells from obese subjects","volume":"9","author":"Bories","year":"2012","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"22617","DOI":"10.1073\/pnas.1009152108","article-title":"IL-4\/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity","volume":"107","author":"Eagle","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1126\/science.1201475","article-title":"Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis","volume":"332","author":"Wu","year":"2011","journal-title":"Science"},{"key":"ref_77","first-page":"917","article-title":"Identification of PPAR\u03b3 ligands with one-dimensional drug profile matching","volume":"7","author":"Simon","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_78","first-page":"349","article-title":"Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers","volume":"34","author":"Stockis","year":"1996","journal-title":"Int. J. Clin. Pharmacol. Ther."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/12\/1817\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:38:54Z","timestamp":1760168334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/12\/1817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":78,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["biom11121817"],"URL":"https:\/\/doi.org\/10.3390\/biom11121817","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]}}}